SEC Comment Letter for Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260) (FBIO) — May 1, 2020

Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)
Date: May 1, 2020 · CIK: 0001429260 · Accession: 0000000000-20-003776

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-35366

Date

May 1, 2020

Author

Lindsay A. Rosenwald, M.D.

Form

UPLOAD

Company

Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)

Letter

United States securities and exchange commission logo May 1, 2020 Lindsay A. Rosenwald, M.D. Executive Chairman, Chief Executive Officer and President Fortress Biotech, Inc. 2 Gansevoort Street, 9th Floor New York, NY 10014 Re:Fortress Biotech, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 17, 2020 File No. 001-35366 Dear Dr. Rosenwald: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mark F. McElreath, Esq.

Show Raw Text

United States securities and exchange commission logo
May 1, 2020
Lindsay A. Rosenwald, M.D.
Executive Chairman, Chief Executive Officer and President
Fortress Biotech, Inc.
2 Gansevoort Street, 9th Floor
New York, NY 10014
Re:Fortress Biotech, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 17, 2020
File No. 001-35366
Dear Dr. Rosenwald:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Mark F. McElreath, Esq.

SecProbe.io